Search
Regulatory Story
Company GlaxoSmithKline PLC
TIDM GSK
Headline Director/PDMR Shareholding
Released 15:55 12-Jul-2019
Number 4344F15

RNS Number : 4344F
GlaxoSmithKline PLC
12 July 2019
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

19

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

62

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

12

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

57

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Mrs S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

19

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

3

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

70

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharmaceuticals Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

19

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

40

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

 

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

 

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 11 July 2019, on shares held through the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.5060

51

 

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

 

 

 

 

 

e)

Date of the transaction

2019-07-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHZLLFFKDFEBBF
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.